Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer
Abstract
Objectives To evaluate CYP3A4 expression in human prostrate cancer (PCa) tissues. Enzymes of the cytochrome P450 (CYP) family are key inactivators of testosterone in the liver and prostate. We previously reported that CYP2B6 is a growth-inhibitory and prognostic factor in human PCa; however, the status of CYP3A4 in PCa remains unclear.Methods We used immunohistochemistry to analyze CYP3A4 expression in 107 human PCa specimens obtained by radical prostatectomy. Stained slides were evaluated for the proportion and staining intensity of positively stained cells. Total immunoreactivity scores (0-8) were obtained as the sum of the proportion and intensity scores. In addition, we estimated the relationship between CYP3A4 status and clinicopathologic features.Results CYP3A4 immunoreactivity was identified in the cytoplasm of prostate cells. The CYP3A4 immunoreactive PCa score (3.6+/-2.6) was significantly lower than that of benign epithelium (4.5+/-2.1; P < .0001). In addition, CYP3A4 immunoreactivity correlated inversely with the Gleason score (P < .0001). Decreased CYP3A4 immunoreactivity was significantly related to a poor prognosis in human PCa (P = .0175).Conclusions We demonstrated differential CYP3A4 expression in prostatic tissues, indicating that decreased CYP3A4 expression may contribute to the development of PCa.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A decrease of CYP3A4 expression is observed in prostate cancer.
“and a decrease of CYP3A4 expression is observed in prostate cancer (Fujimura et al., 2009).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Fujimura et al., 2009
Cites
Conney, A. H. (1982) · PubMed · Cited by 1,557 · see citing works
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,243 · see citing works
Allred, D. C., Clark, G. M., Elledge, R. M., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 769 · see citing works
Yu, Y. P., Landsittel, D. P., Jing, L., Nelson, J. B., Ren, B., Liu, L., McDonald, C., Thomas, R. M., Dhir, R., Finkelstein, S. D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.158 · Cited by 750 · see citing works
Amirimani, B., Walker, A., Weber, B., & Rebbeck, T. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1588 · Cited by 462 · see citing works
Waxman, D. J., Attisano, C., Guengerich, F. P., & Lapenson, D. P. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90655-8 · Cited by 414 · see citing works
Parkinson, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 385 · see citing works
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360 · see citing works
Pascussi, J., Gerbal‐Chaloin, S., Drocourt, L., Maurel, P., & Vilarem, M. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00483-x · Cited by 330 · see citing works
Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Korzekwa, K. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90602-f · Cited by 320 · see citing works
Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L., Tanaka, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2545 · Cited by 202 · see citing works
Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E. T., & Namiki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0130 · Cited by 175 · see citing works
Kittles, R., Chen, W., Panguluri, R. K., Ahaghotu, C., Jackson, A. G., Adebamowo, C., Griffin, R., Williams, T., Ukoli, F. A., Adams-Campbell, L., et al. (2002) · Human Genetics · doi:10.1007/s00439-002-0731-5 · Cited by 164 · see citing works
Constitutive expression of hepatic cytochrome P450 genes
Gonzalez, F. J., & Lee, Y. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.10.8751713 · Cited by 128 · see citing works
CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer, S. J., Conti, D. V., Paris, P. L., Curran, A. P., Casey, G., & Witte, J. S. (2003) · PubMed · Cited by 109 · see citing works
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Čulig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00775a · Cited by 94 · see citing works
Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Ando, Y., Tateishi, T., Sekido, Y., Yamamoto, T., Satoh, T., Hasegawa, Y., Kobayashi, S., Katsumata, Y., Shimokata, K., & Saito, H. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1587 · Cited by 85 · see citing works
Fujimura, T., Takahashi, S., Urano, T., Ogawa, S., Ouchi, Y., Kitamura, T., Muramatsu, M., & Inoue, S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6038 · Cited by 84 · see citing works
Self-citationDetection of cytochrome P450 mRNA transcripts in prostate samples by RT‐PCR
Finnström, N., Bjelfman, C., Söderström, T. G., Smith, G. C., Egevad, L., Norlén, B. J., Wolf, C. R., & Rane, A. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00893.x · Cited by 74 · see citing works
Tayeb, M. T., Clark, C., Haites, N. E., Sharp, L., Murray, G. I., & McLeod, H. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600825 · Cited by 72 · see citing works
Isolation and catalytic activity of cytochrome P-450 from ventral prostate of control rats.
Sundin, M., Warner, M. N., Haaparanta, T., & Gustafsson, J.-Α. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45350-1 · Cited by 64 · see citing works
Hara, T., Nakamura, K., Araki, H., Kusaka, M., & Yamaoka, M. (2003) · PubMed · Cited by 48 · see citing works
Isaacs, J. T., McDermott, I. R., & Coffey, D. S. (1979) · Steroids · doi:10.1016/0039-128x(79)90116-8 · Cited by 42 · see citing works
Isaacs, J. T., McDermott, I. R., & Coffey, D. S. (1979) · Steroids · doi:10.1016/0039-128x(79)90114-4 · Cited by 41 · see citing works
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer
Leskelä, S., Honrado, E., Montero‐Conde, C., Landa, I., Cascón, A., Letón, R., Talavera, P., Cozar, J. M., Concha, A., Robledo, M., et al. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0078 · Cited by 40 · see citing works
Cytochrome P450 2B6 is a growth‐inhibitory and prognostic factor for prostate cancer
Kumagai, J., Fujimura, T., Takahashi, S., Urano, T., Ogushi, T., Horie‐Inoue, K., Ouchi, Y., Kitamura, T., Muramatsu, M., Blumberg, B., et al. (2007) · The Prostate · doi:10.1002/pros.20597 · Cited by 24 · see citing works
Self-citation
Flagged first, then by citations
2 of the 28 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217 · see citing works
“, 2015)) and a decrease of CYP3A4 expression is observed in prostate cancer (Fujimura et al., 2009).”
The Role of CYP3A in Health and Disease
Klyushova, L. S., Perepechaeva, M. L., & Grishanova, A. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10112686 · Cited by 105 · see citing works
van Eijk, M., Boosman, R. J., Schinkel, A. H., Huitema, A. D. R., & Beijnen, J. H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03905-3 · Cited by 100 · see citing works
du Toit, T., Bloem, L. M., Quanson, J. L., Ehlers, R., Serafin, A. M., & Swart, A. C. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.06.009 · Cited by 67 · see citing works
He, B., Shi, L., Qiu, J., Tao, L., Li, R., Yang, L., & Shu-jin, Z. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00657.x · Cited by 53 · see citing works
Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism
Kazuki, Y., Kobayashi, K., Hirabayashi, M., Abe, S., Kajitani, N., Kazuki, K., Takehara, S., Takiguchi, M., Satoh, D., Kuze, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808255116 · Cited by 38 · see citing works
Maksymchuk, O., & Kashuba, V. I. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00133-y · Cited by 36 · see citing works
Narjoz, C., Favre, A., McMullen, J., Kiehl, P., Montemurro, M., Figg, W. D., Beaune, P. H., de Waziers, I., & Rochat, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095532 · Cited by 35 · see citing works
Fujimura, T., Takahashi, S., Urano, T., Tanaka, T., Zhang, W., Azuma, K., Takayama, K., Obinata, D., Murata, T., Horie‐Inoue, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02143.x · Cited by 34 · see citing works
Self-citationFarnesoid X receptor alpha: a molecular link between bile acids and steroid signaling
Baptissart, M., Vega, A., Martinot, E., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1387-0 · Cited by 32 · see citing works
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
Fujimura, T., Takayama, K., Takahashi, S., & Inoue, S. (2018) · Cancers · doi:10.3390/cancers10020029 · Cited by 31 · see citing works
Self-citationMaguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T. J., Doherty, D. F., Campbell, M. J., McClean, S., & Thompson, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.007 · Cited by 30 · see citing works
Chen, J.-H., He, H.-C., Jiang, F.-N., Militar, J., Ran, P.-Y., Qin, G.-Q., Cai, C., Chen, X.-B., Zhao, J., Mo, Z.-Y., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-0088-5 · Cited by 30 · see citing works
Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer
Wang, J., Yu, L., Jiang, H., Zheng, X., & Zeng, S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000008 · Cited by 27 · see citing works
Ahn, J., Park, S.-G., Zuniga, B., Bera, A., Song, C. S., & Chatterjee, B. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.10.012 · Cited by 26 · see citing works
Glucosinolate-Degradation Products as Co-Adjuvant Therapy on Prostate Cancer in Vitro
Núñez-Iglesias, M. J., Novío, S., Garcı́a, C., Pérez-Muñuzuri, M. E., Soengas, P., Cartea, M. E., Velasco, P., & Freire‐Garabal, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20204977 · Cited by 21 · see citing works
Vitamin D receptor agonist EB1089 is a potent regulator of prostatic “intracrine” metabolism
Doherty, D. F., Dvorkin, S., Rodriguez, E. P., & Thompson, P. D. (2013) · The Prostate · doi:10.1002/pros.22748 · Cited by 18 · see citing works
Sakurai, K., Enomoto, K., Matsuo, S., Amano, S., & Shiono, M. (2011) · Surgery Today · doi:10.1007/s00595-009-4328-7 · Cited by 18 · see citing works
Paquin, A., Oufqir, Y., Sevrioukova, I. F., Reyes‐Moreno, C., & Bérubé, G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113496 · Cited by 14 · see citing works
Reyes‐Hernández, O. D., Vega, L., Jiménez-Ríos, M. Á., Martínez-Cervera, P. F., Lugo-García, J. A., Cadena, L. H., Ostrosky‐Wegman, P., Orozco, L., & Elizondo, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099974 · Cited by 13 · see citing works
Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells
Smith, K. W., Thompson, P. D., Rodriguez, E. P., Mackay, C. L., & Cobice, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.059 · Cited by 13 · see citing works
Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion
Zhang, R., Huang, M., Wang, H., Wu, S., Yao, J., Ge, Y., Lu, Y., & Hu, Q. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.597527 · Cited by 12 · see citing works
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
Alonso‐Peña, M., Sánchez-Martín, A., Sanchon-Sanchez, P., Soto-Muñiz, M., Espinosa-Escudero, R. A., & Marı́n, J. J. G. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.006 · Cited by 8 · see citing works
Impact of hepatic malignancy on CYP3A4 gene expression
Fahy, B. N., Guo, T., & Ghose, R. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.06.008 · Cited by 5 · see citing works
Bondarenko, L. B. (2013) · Journal of Physiobiochemical Metabolism · doi:10.4172/2324-8793.1000108 · Cited by 4 · see citing works
Hu, B., Zhang, X., Zhu, S., Wang, C., Deng, Z., Wang, T., & Wu, Y. (2024) · European journal of medical research · doi:10.1186/s40001-024-01672-3 · Cited by 3 · see citing works
Маковецька, А. М., Турова, Л. О., & Савельєва, М. В. (2023) · Men’s Health Gender and Psychosomatic Medicine · doi:10.37321/ujmh.2022.1-2-09 · Cited by 2 · see citing works
Liu, M., Tan, L., Li, X., Li, H., Zhang, Y., Zi, X., Ge, C., & Wang, K. (2025) · Poultry Science · doi:10.1016/j.psj.2025.104916 · Cited by 1 · see citing works
Characteristics Of Androgen Metabolism In Prostate Diseases
Roussev, B. H., & Galunska, B. T. (2018) · Varna Medical Forum · doi:10.14748/vmf.v7i2.5137
Amadi, C., Okafor, J. C., & Agbo, E. O. (2025) · Pathology and Laboratory Medicine · doi:10.11648/j.plm.20250901.11
Drug metabolism in cancer patients
Huang, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29289-7.00024-2
Hu, B., Zhang, X., Zhu, S., Wang, C., Deng, Z., Wang, T., & Wu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26674997
Hu, B., Zhang, X., Zhu, S., Wang, C., Deng, Z., Wang, T., & Wu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26674994
BindingDB Entry 50014507: Innovative C
BindingDB (2022) · UC San Diego · doi:10.7270/q2s1869n
- Authors
- Fujimura, T., Takahashi, S., Urano, T., Kumagai, J., Murata, T., Takayama, K., Ogushi, T., Horie-Inoue, K., Ouchi, Y., Kitamura, T., Muramatsu, M., Homma, Y., & Inoue, S.
- Affiliations
- The University of Tokyo (JP)
- Nihon University (JP)
- Saitama Medical University (JP)
- Corresponding author
- Fujimura, Tetsuya
- ORCID
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 74
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2109023371
- Cited by
- 34
- References
- 28
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- CYP3A4, prostate cancer, testosterone metabolism, Gleason score, prognosis, immunohistochemical expression, benign prostatic epithelium, CYP2B6
- MeSH terms
- Aged, Cytoplasm, Epithelium, Humans, Immunohistochemistry, Lymph Nodes, Lymphatic Metastasis, Male, Middle Aged, Prognosis, Prostate, Prostatic Neoplasms, Hepatocytes, Cytochrome P-450 CYP3A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
